A study assessing the effectiveness and tolerability of Lipikar AP+ M in patients with xerosis or atopic dermatitis (AD)

Emollients are recommended as basic skin care in patients with any severity of Atopic Dermatitis (AD). Data from a previous randomized double-blind study suggests that Lipikar AP + M, comprising Aqua Posae Filiformis, Microresyl, shea butter, and niacinamide had significantly greater improvements in pruritus versus standard emollient in patients with moderate-to-severe AD on systemic treatment. ¹

   This observational study assessed the impact of lipikar AP + M on symptom management and health-related quality of life (HRQoL) in patients aged >16 years with mild-to-severe xerosis, a history of skin disease, and prone to AD. Patients with severe/very severe AD receiving oral corticosteroids or other oral immunosuppressants were excluded. The study was conducted by dermatologists in the United Kingdom. Patients were recommended to use Lipikar AP + M once or twice daily. Questionnaires evaluated effectiveness, satisfaction, and tolerability by patients and physicians, and HRQoL by patients at baseline (Visit 1; 0 weeks) and end-of-study (Visit 2; 6–8 weeks).

   In total, 98 patients were evaluated: mean (standard deviation [SD]) age, 42 (16) years; 58.2% female. AD was the most common skin condition (48.5%), followed by severe xerosis other than AD (22.7%), senile xerosis (12.4%), psoriasis (6.2%), and other skin conditions (10.3%). The mean disease duration was 21 years for patients with AD or psoriasis and 6–8 years for those with xerosis. Physicians recommended treatment over a mean of 9.2 (3.0) weeks, and twice-daily application for most patients (71.6%). 

RESULTS